AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 51 min read$RPRX

Urist Marshall sold $236K of RPRX

Urist Marshall (EVP, Research & Investments) sold 4,126 shares of Royalty Pharma plc (RPRX) at $57.10 ($0.24M total) on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Urist Marshall
Published Oct 5, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RPRX
Bearish
medium confidence
Mentioned
$RPRX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RPRXBearishLow
01

Why it matters

A modest insider sell may cause short-term price softness but is unlikely to drive major moves.

02

Market read

The filing provides fresh data on insider activity, useful for short-term traders monitoring sell pressure.

03

What to watch

The insider's holdings were already low; the sale may not reflect company fundamentals.

Relevance 3/10Novelty 3/10Timing: today

Background

Form 4 filings disclose insider transactions and are used to gauge insider sentiment.

Company-level read

Ticker impact

$RPRXBearishMedium confidence
Context

EVP Urist Marshall sold 4,126 shares for $235,594.60 via a 10b5-1 plan, reducing holdings to zero.

Expected impact

potential modest downside as the market prices in the insider sell

Evidence & confidence

A $236K sale by a senior officer signals possible concerns, but the amount is modest relative to market cap.

Market effects

Sector

Minimal impact on the broader pharma sector.

Regional

No significant regional effect.

Global

Limited to investors tracking insider activity.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a red flag.

Key entities

  • Company
    Royalty Pharma plc

    US-listed specialty pharma company (ticker RPRX).

  • Person
    Urist Marshall

    EVP, Research & Investments at Royalty Pharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RPRX insider trading history →

Related articles

SEP 25
$RVMDMedAI 8/10

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

Revolution Medicines (RVMD) received FDA breakthrough therapy designation for its pancreatic cancer drug, RASONQUE. The stock has surged 330% in a year. Royalty Pharma (RPRX) offers diversified exposure to RVMD and other drugs, with a 1.6% dividend yield. RPRX is up 60% in a year, providing a balanced risk-reward option.

aol.com3 min
SEP 10
$RPRXMedAI 8/10

Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?

Royalty Pharma (RPRX) reported that pelacarsen failed its Phase 3 trial, shifting financial focus to Spinraza royalties. The company provided $500M to Ionis (IONS) in 2023, with $150M allocated to pelacarsen. RPRX expects to recover its investment through Spinraza, aiming for a modest return. The failure limits pelacarsen's potential upside, and recovery depends on Spinraza's performance.

insidermonkey.com2 min
SEP 8
$NVSHighAI 8/10

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

Novartis AG (NYSE:NVS) stock fell sharply after its Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed the primary endpoint. The company also reported that the pelacarsen Phase 3 Lp(a)HORIZON trial for cardiovascular outcomes failed. Both Ionis Pharmaceuticals (NASDAQ:IONS) and Royalty Pharma (NASDAQ:RPRX) saw stock declines due to their ties with Novartis.

aol.com2 min
SEP 8
$NVSHighAI 8/10

Why Is Novartis Stock Falling Today? - Novartis (NYSE:NVS), Ionis Pharmaceuticals (NASDAQ:IONS), Royalty

Novartis (NYSE:NVS) stock fell sharply after Phase 3 HARBOR trial for del-desiran in myotonic dystrophy type 1 missed primary endpoint. The company also reported that the pelacarsen cardiovascular trial failed to meet its primary endpoint. Ionis Pharmaceuticals (NASDAQ:IONS) and Royalty Pharma (NASDAQ:RPRX) shares also declined due to the trial results. Novartis is evaluating the data and plans to discuss next steps with health authorities.

benzinga.com2 min